Biopharma firm Biocon’s wholly owned subsidiary, Biocon Generics, has acquired the oral strong dosage manufacturing facility of US-based Eywa Pharma Inc situated in Cranbury, New Jersey for $7.7 million (Rs 63 crore). The acquisition is efficient September 1.
The corporate acknowledged that this facility within the US may additional broaden its capability as much as two billion tablets or capsules per yr.
As a part of the acquisition, the manufacturing facility’s workforce will transition to Biocon Generics Inc.
Siddharth Mittal, the Managing Director and CEO of Biocon acknowledged, “The acquisition of this USFDA-approved facility will complement Biocon’s existing manufacturing capabilities and strengthen our foothold in the United States. The acquisition will also enable us to add oral solid dosage capacities for new products earlier than originally planned and ensure supply continuity through diversifying our manufacturing infrastructure.”
This newest acquisition comes on the heels of Biocon’s growth enterprise, as final yr, its subsidiary, Biocon Biologics, efficiently accomplished the acquisition of the worldwide biosimilars enterprise of its companion, Viatris Inc., in a deal value $3.33 billion
First Printed: Sep 02 2023 | 5:33 PM IST